QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 1.93
$ 1.84
$ 1.70 x 15,000
$ 2.30 x 100
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-09-2025 03-31-2025 10-Q
4 03-17-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-10-2024 03-31-2024 10-Q
8 03-14-2024 12-31-2023 10-K
9 11-06-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-27-2023 12-31-2022 10-K
13 11-14-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 03-31-2022 12-31-2021 10-K
17 11-15-2021 09-30-2021 10-Q
18 08-16-2021 06-30-2021 10-Q
19 05-14-2021 03-31-2021 10-Q
20 03-30-2021 12-31-2020 10-K
21 10-29-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 06-01-2020 03-31-2020 10-Q
24 03-12-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-06-2019 03-31-2019 10-Q
28 03-18-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 03-06-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-08-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-08-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 protalix-biotherapeutics-q3-eps-003-misses-006-estimate-sales-17673m-miss-17866m-estimate

Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate ...

 protalix-biotherapeutics-unit-requests-reexamination-of-negative-opinion-issued-by-chmp-related-to-proposed-dosing-regimen-of-2-mgkg-body-weight-infused-every-4-weeks-for-elfabrio

Chiesi Global Rare Diseases, a business unit of the Chiesi Group, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), have...

 why-is-protalix-biotherapeutics-stock-falling-on-friday

EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data ...

 protalix-biotherapeutics-q2-sales-15658m-beat-13546m-estimate

Protalix BioTherapeutics (AMEX:PLX) reported quarterly sales of $15.658 million which beat the analyst consensus estimate of $1...

 protalix-biotherapeutics-q1-eps-005-misses-003-estimate-sales-1011m-miss-2160m-estimate

Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate ...

 protalix-biotherapeutics-says-with-debt-fully-repaid-its-well-positioned-to-execute-strategy-through-2025-and-beyond

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start ...

 protalix-biotherapeutics-fy-2024-gaap-eps-004-beats-001-estimate-sales-5340m-miss-5394m-estimate

Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION